“The pitches always sounded promising: A new software app could track glucose levels for people with diabetes or soothe the brains of insomniacs. Most pharma executives would politely smile and nod, but then park their money somewhere else.
Backed by a growing body of evidence, software is itself becoming a prescription for diseases ranging from depression to heart disease, and drug companies are starting to take notice. In the past couple years, many have quickly ramped up their investments in digital startups, infusing software-based therapies into pipelines once dominated by traditional medicines.
These products, known broadly as digital therapeutics, deliver treatment to patients through video games, smartphone apps, and sensors buried in pills or attached to medication dispensers. They are designed to stimulate changes in behavior — and in some cases brain function — to help patients control a variety of illnesses and chronic conditions.” Keep reading article.
News in Context:
- Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
- Pear Therapeutics raises $50M to develop and market a portfolio of digital therapeutics for mental health
- Mindstrong Health raises $14 million to modernize the diagnosis and treatment of neuropsychiatric disorders via artificial intelligence (AI) and smartphones
- Pending FDA review and approval, research findings pave way for Akili’s EVO to become first brain training platform prescribed for ADHD
- The FDA creates new Digital Health unit to reimagine regulatory paths in the age of scalable, AI-enhanced innovation
- Presentations by digital therapeutics pioneers during the 2016 SharpBrains Virtual Summit: